Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Passive immunization against cytomegalovirus in allograft recipients. The Rotterdam heart transplant program experience (1993)
    Springer
    Infection 21 (1993), S. 195-200 
    Details
    ISSN: 1439-0973
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung An 146 Herztransplantationspatienten untersuchten wir den Effekt passiver Immunisierung gegen CMV. Die 65 seronegativen Herzempfänger wurden peri- und postoperativ prophylaktisch mit Anti-CMV-Immunglobulin behandelt. 29 dieser 65 Patienten erhielten ein seropositives Spenderherz. Bei 21 von 65 seronegativen und bei 40 von 81 seropositiven Empfängern kam es zur Infektion (Unterschied nicht signifikant). Die Inzidenz von CMV-Infektionen war bei seronegativen Empfängern eines entsprechenden Spenderherzens (3/34) signifikant niedriger als bei seronegativen Empfängern eines positiven Spenderherzens und niedriger als bei seropositiven Empfängern, jedoch ergab sich kein signifikanter Unterschied zwischen den beiden letztgenannten Gruppen (18/29 versus 40/81). Obwohl primäre Infektionen häufiger zur CMV-Erkrankung führten als sekundäre Infektionen (11/21 versus 10/40), ergab sich kein Unterschied in der Häufigkeit seronegativer und seropositiver Patienten (11/65 versus 10/81), oder im Schweregrad der Symptomatik nach primärer beziehungsweise sekundärer Infektion. Bei allen Patienten, die das Herz eines seropositiven Spenders erhielten, ergab sich eine höhere Inzidenz an CMV-Erkrankungen, als bei denen, die einen seronegativen Spender hatten. Nach der Transplantation eines Herzens von einem seropositiven Spender war jedoch bei unseren passiv immunisierten seronegativen Patienten die gleiche Inzidenz (27%) von CMV-Erkrankungen zu beobachten wie bei den Patienten mit natürlich erworbener Seropositivität. In der Prävalenz der koronaren Herzkrankheit ergab sich kein Unterschied zwischen Patienten mit und ohne CMV-Infektion oder Erkrankung. Demzufolge hängt das Auftreten einer CMV-Infektion und Erkrankung bei Anwendung des gegenwärtigen Schemas zur passiven Immunisierung weitgehend vom serologischen Status des Spenders ab.
    Notes: Summary We analyzed the results of passive immunization against CMV in 146 heart transplant recipients. The 65 seronegative recipients were prophylactically treated with anti-CMV immunoglobulins during and after the operation. Twenty-nine of these 65 patients received a seropositive donor heart. CMV infection occurred in 21/65 seronegative and in 40/81 seropositive recipients (difference not significant). The incidence of CMV infection in seronegative recipients of a CMV-matched donor heart (3/34) was significantly lower than in seronegative recipients of a positive donor heart and lower than in seropositive recipients, but no significant difference in infection rate was found between the two latter groups (18/29 vs. 40/81). Although primary infection more frequently resulted in CMV disease than secondary infection (11/21 vs. 10/40) no difference in incidence of disease was noted between seronegative and seropositive patients (11/65 vs. 10/81), nor was there a difference in the severity of symptoms following primary or secondary infection. There was a higher incidence of CMV disease in all patients who received a heart from a seropositive donor versus a seronegative donor. However, after transplantation of a heart from a seropositive donor the incidence (27%) of CMV disease observed in our passively immunized seronegative patients was the same as in the patients with naturally acquired seropositivity. There was no difference in the prevalence of coronary artery disease between patients with and without CMV infection or disease. We conclude that using the current passive immunization scheme the occurrence of CMV infection and disease is largely dependent on the serostatus of the donor.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01728886
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Redundancy of the cytokine network in the development of rejection after clinical heart transplantation (1998)
    Springer
    Transplant international 11 (1998), S. S512 
    Details
    ISSN: 1432-2277
    Keywords: Key words Anti-interleukin-2 receptor monoclonal antibodies ; Prophylaxis ; Interleukin-15 ; Redundancy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We used reverse transcriptase–polymerase chain reaction analysis to study the effects of anti-rejection prophylaxis with an anti-interleukin (IL)-2 receptor (IL-2R) monoclonal antibody (BT563) on the allogeneic process by analyzing intragraft IL-2, IL-4, and IL-15 mRNA expression. Analysis showed an association between rejection and intragraft IL-2 mRNA and IL-4 mRNA transcription, whereas IL-15 was consitutively expressed: IL-2 62 % (8/13) during rejection versus 23 % (8/35) during immunological quiescence (P 〈 0.01); IL-4 69 % versus 23 % (P 〈 0.01). BT563 therapy influenced the intragraft mRNA expression of IL-2 and IL-4 but not of IL-15. In endomyocardial biopsies (EMB) showing rejection, mRNA expression of IL-2 was detectable in 40 % (2/5) during BT563 treatment versus 75 % (6/8) in the absence of BT563; for IL-4, 23 % versus 88 %, respectively. In contrast, IL-15 mRNA transcription was not affected. Quantitative analysis in rejection EMB showed comparable IL-15 mRNA levels during and after BT563 treatment. This study demonstrates that therapeutic intervention within the IL-2-dependent T-cell activation cascade does not completely prevent rejection. Other cytokines, such as IL-15, may participate in IL-2-independent rejections.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001470050530
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Donor-specific CTL frequencies in peripheral blood in relation to graft vascular disease after clinical heart transplantation (1998)
    Springer
    Transplant international 11 (1998), S. S364 
    Details
    ISSN: 1432-2277
    Keywords: Key words Peripheral blood ; Chronic rejection ; CTL frequencies
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Cellular mechanisms may play a role in the development of graft vascular disease (GVD). We previously demonstrated that GVD correlated with an increase of donor-specific T-helper 1 cytokine production by graft-infiltrating lymphocytes but not by peripheral blood mononuclear cells (PBMC). These T-helper 1 cytokines aid the generation of cytotoxic T-lymphocytes (CTL). In the present report, we investigated whether there is a relationship between the frequency of donor-specific CTL precursors (pCTL) in PBMC and the development of GVD. We tested PBMC samples of five patients with GVD and five patients without GVD in the periods 3–6 months, 1 year, and 3 years after heart transplantation. At all time points, GVD was not related to the number of pCTL. In conclusion, donor-specific cellular tests in peripheral blood could not be related to GVD. Apparently, donor-specific reactions associated with the induction of GVD can only be monitored in the graft.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001470050499
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    C-reactive protein in the monitoring of acute rejection after heart transplantation (1998)
    Springer
    Transplant international 11 (1998), S. 361-364 
    Details
    ISSN: 1432-2277
    Keywords: Key words Heart transplantation ; monitoring ; C-reactive protein ; Monitoring protein ; heart transplantation ; C-reactive protein ; C-reactive protein ; acute rejection ; heart
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Histological examination of endomyocardial biopsy (EMB) is the main technique for rejection surveillance after heart transplantation. This technique is elaborate, inconvenient for the patient, and not without complications. We prospectively analyzed whether the measurement of C-reactive protein (CRP), an acute phase protein that quickly rises when there is inflammation, can serve as a marker for immunological quiescence and as an indicator for withholding EMB. During a 6-month period, CRP was measured in all patients referred for EMB as part of the routine follow-up after heart transplantation. Acute rejection in patients with a follow-up of more than 1 year was rare (1/76). In the majority of cases, EMB was taken within the 1-year post-transplantation (170/246 = 69 %). In 71/170 biopsies (42 %), CRP was ≤ 1; in the other 99/170 (58 %), CRP was ≥ 2. When CRP was ≤ 1, acute rejection was diagnosed in 12/70 cases (17 %). In contrast, acute rejection was found in 28/99 cases (28 %) with CRP ≥ 2 (P = 0.1). Although CRP is elevated more often in the presence of acute rejection, its sensitivity does not allow CRP to replace the routine performance of EMB for monitoring rejection after heart transplantation. We did, however, find a prognostic significance with regard to the effect of rejection treatment: in all acute rejections with a CRP ≤ 3 (n = 11), steroids were effective.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001470050158
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...